| SANOFI |
SANOFI |
90%
|
Teva entered into an exclusive collaboration with Sanofi to co-develop and co-commercialize Teva's duvakitug (anti-TL1A, TEV-’574), a novel anti-TL1A medicine for the potential treatment of Crohn’s d… |
| JNJ |
Johnson & Johnson |
72%
|
ration contained biosimilar candidates addressing multiple therapeutic areas, including proposed biosimilars to Humira ® (adalimumab) and Stelara ® (ustekinumab). Under the terms of the agreement, Al… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from TEVA graph: ration contained biosimilar candidates addressing multiple therapeutic areas, including proposed biosimilars to Humira… |
| KR |
The Kroger Co. |
72%
|
hese allegations. Under the terms of the settlement, which includes no admission of wrongdoing, Teva is required to pay $ 25 million, consisting of $ 10 million that was paid in the fourth quarter of… |
| KR |
The Kroger Co. |
72%
|
Reciprocal relationship from KR graph: Reciprocal relationship from TEVA graph: hese allegations. Under the terms of the settlement, which includes no admission of wrongdoing, Teva is required to pay… |
| MCK |
McKesson Corporation |
72%
|
Reciprocal relationship from MCK graph: Reciprocal relationship from TEVA graph: Reciprocal relationship from MCK graph: Reciprocal relationship from TEVA graph: Reciprocal relationship from MCK grap… |
| MCK |
McKesson Corporation |
72%
|
80 AJOVY 84 63 42 COPAXONE 48 63 64 AUSTEDO 46 15 8 Other* 349 278 257 Total $ 2,463 $ 2,351 $ 2,352 17 1 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Stat… |
| ALDER-BIOPHARMACEUTICALS-INC |
ALDER-BIOPHARMACEUTICALS-INC |
62%
|
age forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments and creams. We offer a broad range of 5 Table of Contents basic chemical entities, as well as s… |
| AMERISOURCEBERGEN-CORPORATION |
AMERISOURCEBERGEN-CORPORATION |
62%
|
80 AJOVY 84 63 42 COPAXONE 48 63 64 AUSTEDO 46 15 8 Other* 349 278 257 Total $ 2,463 $ 2,351 $ 2,352 17 1 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Stat… |
| ASSET-GROUP |
ASSET-GROUP |
62%
|
SR&A for chargebacks and Medicaid and other governmental allowances were $1,638 million. Provisions for chargebacks involve estimates of usage by indirect buyers with varying contract prices and whol… |
| EAGLE-PHARMACEUTICALS-INC |
EAGLE-PHARMACEUTICALS-INC |
62%
|
ery day. Teva was incorporated in Israel on February 13, 1944 and is the successor to a number of Israeli corporations, the oldest of which was established in 1901. 2 Table of Contents Our Business S… |
| JKI-CO-LTD |
JKI-CO-LTD |
62%
|
urers, to independent retail pharmacies, pharmacy retail chains, hospitals and physician offices in the United States. Anda is able to compete in the distribution market by maintaining a broad portfo… |
| J-WILL-PARTNERS-CO-LTD |
J-WILL-PARTNERS-CO-LTD |
62%
|
urers, to independent retail pharmacies, pharmacy retail chains, hospitals and physician offices in the United States. Anda is able to compete in the distribution market by maintaining a broad portfo… |
| ONE-PLAINTIFF-AETNA-INC |
ONE-PLAINTIFF-AETNA-INC |
62%
|
s of the settlement – $ 10 million in the fourth quarter of 2024, and $ 15 million in 2025 – which includes no admission of wrongdoing. Teva has recognized a provision for the resolution of this matt… |
| OPERATIONS-TEVA-PHARMACEUTICAL-INDUSTRIES-LIMITE |
OPERATIONS-TEVA-PHARMACEUTICAL-INDUSTRIES-LIMITE |
62%
|
NOTE 1 — Significant accounting policies: a. General: Operations Teva Pharmaceutical Industries Limited (the “Parent Company”), headquartered in Israel, together with its subsidiaries and associated … |
| PRICEWATERHOUSECOOPERS-INTERNATIONAL-LIMITED |
PRICEWATERHOUSECOOPERS-INTERNATIONAL-LIMITED |
62%
|
December 31, 2024, consolidated SR&A for chargebacks and Medicaid were $1,497 million. Provisions for chargebacks involve estimates of usage by retailers and other indirect buyers with varying contra… |
| TAKEDA-PHARMACEUTICAL-COMPANIES-LIMITED |
TAKEDA-PHARMACEUTICAL-COMPANIES-LIMITED |
62%
|
urers, to independent retail pharmacies, pharmacy retail chains, hospitals and physician offices in the United States. Anda is able to compete in the distribution market by maintaining a broad portfo… |
| TAKEDA-PHARMACEUTICAL-COMPANY-LTD |
TAKEDA-PHARMACEUTICAL-COMPANY-LTD |
62%
|
tion and supply of the biosimilar product candidates and Teva will exclusively commercialize the products in the U.S. In July 2023, Alvotech and Teva amended their collaboration agreement, adding two… |
